aTyr Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview

aTyr Pharma

08/08/2025 14:53

aTyr Pharma Inc ATYR.OQ ATYR.O is expected to  show a rise in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2025

The San Diego California-based  company is expected to report revenue of $1.714 million, according to the mean estimate from 7 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for aTyr Pharma Inc is for a loss of 16 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 2.9% in the last three months. ‚Äč

Wall Street's median 12-month price target for aTyr Pharma Inc is $18.00, about 70.9% above its last closing price of $5.24

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2025
-0.18
-0.18
-0.22
Missed
-19.3
Mar. 31 2025
-0.18
-0.19
-0.17
Beat
10.5
Dec. 31 2024
-0.21
-0.23
-0.18
Beat
20.4‚Äč
Sep. 30 2024
-0.22
-0.22
-0.23
Missed
-4.5
‚Äč‚ÄčJun. 30 2024
-0.24
-0.24
-0.23
Beat
3.4
Mar. 31 2024
-0.25
-0.24
-0.23
Beat
2.5‚Äč
Dec. 31 2023
-0.24
-0.25
Missed
-5
Sep. 30 2023
-0.22
-0.23
-0.20
Beat
11.5

This summary was machine generated August 8 at 13:53 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)